162. 類天疱瘡(後天性表皮水疱症を含む。) Pemphigoid Clinical trials / Disease details
臨床試験数 : 83 / 薬物数 : 128 - (DrugBank : 51) / 標的遺伝子数 : 33 - 標的パスウェイ数 : 142
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2020-000287-32-GR (EUCTR) | 04/11/2021 | 13/09/2021 | A study to investigate the use of benralizumab in patients with bullous pemphigoid | A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab as a Treatment Option for Patients with Bullous Pemphigoid (FJORD) - FJORD | Bullous Pemphigoid MedDRA version: 21.1;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Trade Name: Fasenra Product Name: benralizumab Product Code: MEDI-563 INN or Proposed INN: benralizumab Other descriptive name: benralizumab | AstraZeneca AB | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 120 | Phase 3 | France;United States;Greece;Spain;Australia;Bulgaria;Israel;Germany;Italy;Japan;China | ||
2 | EUCTR2020-000287-32-DE (EUCTR) | 12/04/2021 | 16/10/2020 | A study to investigate the use of benralizumab in patients with bullous pemphigoid | A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab as a Treatment Option for Patients with Bullous Pemphigoid (FJORD) - FJORD | Bullous Pemphigoid MedDRA version: 21.1;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Trade Name: Fasenra Product Name: benralizumab Product Code: MEDI-563 INN or Proposed INN: benralizumab Other descriptive name: benralizumab | AstraZeneca AB | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 120 | Phase 3 | United States;France;Greece;Spain;Australia;Israel;Bulgaria;Germany;Japan;Italy;China | ||
3 | NCT04612790 (ClinicalTrials.gov) | March 31, 2021 | 12/10/2020 | A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid. | A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab as a Treatment Option for Patients With Bullous Pemphigoid (FJORD) | Bullous Pemphigoid | Biological: Benralizumab;Biological: Placebo | AstraZeneca | NULL | Recruiting | 18 Years | 130 Years | All | 120 | Phase 3 | United States;Australia;Bulgaria;China;France;Germany;Greece;Israel;Italy;Japan;Spain |
4 | JPRN-jRCT2071210014 | 26/03/2021 | 26/04/2021 | A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab as a Treatment Option for Patients With Bullous Pemphigoid. | The purpose of this study is to investigate the use of benralizumab is effective in the treatment of patients symptomatic Bullous Pemphigoid (BP). - FJORD | Bullous Pemphigoid | This study is designed to assess the efficacy and safety of a benralizumab 60 mg loading dose followed by repeat dosing of subcutaneously (SC) administered benralizumab 30 mg versus placebo in adult participants with symptomatic BP. Following screening, about 120 eligible participants will be randomized 1:1 to receive either benralizumab or placebo. Double-blind treatment period (0w-36w): In the benralizumab group, 60 mg initially and 30 mg thereafter are subcutaneously administered every 4 weeks. In the placebo group, placebo is subcutaneously administered every 4 weeks. Open-label extension period (36w-): All participants who complete the double-blind dosing period will be given the option of receiving benralizumab 30 mg subcutaneously every 4 weeks. | Hibi Kazushige | NULL | Recruiting | >= 18age old | Not applicable | Both | 12 | Phase 3 | United States;Australia;Bulgaria;France;Germany;Israel;Italy;Spain;Japan |
5 | EUCTR2020-000287-32-FR (EUCTR) | 09/02/2021 | 03/11/2020 | A study to investigate the use of benralizumab in patients with bullous pemphigoid | A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab as a Treatment Option for Patients with Bullous Pemphigoid - FJORD | Bullous Pemphigoid MedDRA version: 21.1;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Name: benralizumab Product Code: MEDI-563 INN or Proposed INN: benralizumab Other descriptive name: benralizumab | AstraZeneca AB | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 120 | Phase 3 | United States;France;Spain;Australia;Israel;Bulgaria;Germany;Japan;Italy | ||
6 | EUCTR2020-000287-32-IT (EUCTR) | 22/01/2021 | 24/05/2021 | A study to investigate the use of benralizumab in patients with bullous pemphigoid | A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab as a Treatment Option for Patients with Bullous Pemphigoid - FJORD | Bullous Pemphigoid MedDRA version: 21.1;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Name: Benralizumab Product Code: [MEDI-563] INN or Proposed INN: Benralizumab | ASTRAZENECA AB | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 120 | Phase 3 | France;United States;Spain;Australia;Bulgaria;Israel;Germany;Japan;Italy | ||
7 | EUCTR2020-000287-32-BG (EUCTR) | 02/12/2020 | 06/10/2020 | A study to investigate the use of benralizumab in patients with bullous pemphigoid | A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab as a Treatment Option for Patients with Bullous Pemphigoid (FJORD) - FJORD | Bullous Pemphigoid MedDRA version: 21.1;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Trade Name: Fasenra Product Name: benralizumab Product Code: MEDI-563 INN or Proposed INN: benralizumab Other descriptive name: benralizumab | AstraZeneca AB | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 120 | Phase 3 | France;United States;Greece;Spain;Australia;Israel;Bulgaria;Germany;Italy;Japan;China |